Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function ...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily characterized by dopaminergic neuronal loss in the substantia nigra and intracellular accumulation of misfolded ...
People with Parkinson’s disease have α-synuclein clumps in the brain, but these aggregates are not the only thing clogging them up. Constipation plagues many PD patients, often decades before motor ...
– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples with 81% accuracy through the direct detection of EV-bound aggregated alpha-synuclein proteins – – With no ...
The exact molecular mechanism via which α-synuclein, the main protein involved in Parkinson’s pathogenesis, aggregates is yet to be understood completely. In a recently published study, a team of ...
Scientists have uncovered a potential new mechanism whereby α-synuclein pathology spreads. Like black holes, large densities of α-synuclein pull in surrounding matter. Among the victims trapped in ...
Copyright: © 2025 The Author(s). Published by Elsevier B.V. Smartwatch data has been found to identify Parkinson's disease (PD) several years before the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results